218 related articles for article (PubMed ID: 8941480)
1. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin.
ter Braak EW; Woodworth JR; Bianchi R; Cerimele B; Erkelens DW; Thijssen JH; Kurtz D
Diabetes Care; 1996 Dec; 19(12):1437-40. PubMed ID: 8941480
[TBL] [Abstract][Full Text] [Related]
2. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures.
Woodworth JR; Howey DC; Bowsher RR; Brunelle RL; Rowe HM; Compton J; Cerimele B
Diabetes Care; 1994 May; 17(5):366-71. PubMed ID: 8062601
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects.
de la Peña A; Yeo KP; Linnebjerg H; Catton E; Reddy S; Brown-Augsburger P; Morrow L; Ignaut DA
J Diabetes Sci Technol; 2015 Jul; 9(4):824-30. PubMed ID: 25697717
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites.
Leohr JK; Dellva MA; LaBell E; Coutant DE; Linnebjerg H
Clin Ther; 2022 Jun; 44(6):836-847. PubMed ID: 35577602
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.
Leohr J; Dellva MA; LaBell E; Coutant DE; Klein O; Plum-Moerschel L; Zijlstra E; Linnebjerg H
Clin Ther; 2020 Sep; 42(9):1762-1777.e4. PubMed ID: 32900535
[TBL] [Abstract][Full Text] [Related]
7. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
[TBL] [Abstract][Full Text] [Related]
8. Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes.
Milicevic Z; Profozic V; Wyatt J; Ristic S; Woodworth JR; Seger M; Kaliterna D; Bates P; Metelko Z
Diabet Med; 2001 Jul; 18(7):562-6. PubMed ID: 11553186
[TBL] [Abstract][Full Text] [Related]
9. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase.
Vaughn DE; Yocum RC; Muchmore DB; Sugarman BJ; Vick AM; Bilinsky IP; Frost GI
Diabetes Technol Ther; 2009 Jun; 11(6):345-52. PubMed ID: 19459762
[TBL] [Abstract][Full Text] [Related]
10. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
[TBL] [Abstract][Full Text] [Related]
11. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
[TBL] [Abstract][Full Text] [Related]
12. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
Roach P; Woodworth JR
Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
[TBL] [Abstract][Full Text] [Related]
14. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
Pettis RJ; Ginsberg B; Hirsch L; Sutter D; Keith S; McVey E; Harvey NG; Hompesch M; Nosek L; Kapitza C; Heinemann L
Diabetes Technol Ther; 2011 Apr; 13(4):435-42. PubMed ID: 21355718
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus.
Czock D; Aisenpreis U; Rasche FM; Jehle PM
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):492-7. PubMed ID: 14703957
[TBL] [Abstract][Full Text] [Related]
16. Insulin lispro: its role in the treatment of diabetes mellitus.
Campbell RK; Campbell LK; White JR
Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409
[TBL] [Abstract][Full Text] [Related]
17. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro.
Rave KM; Nosek L; de la Peña A; Seger M; Ernest CS; Heinemann L; Batycky RP; Muchmore DB
Diabetes Care; 2005 Oct; 28(10):2400-5. PubMed ID: 16186270
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro.
Chao M; Wang W; Zhang Y; Lu X; Meng J; Ning G
Endocrine; 2010 Aug; 38(1):48-52. PubMed ID: 20960101
[TBL] [Abstract][Full Text] [Related]
20. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin.
Heise T; Weyer C; Serwas A; Heinrichs S; Osinga J; Roach P; Woodworth J; Gudat U; Heinemann L
Diabetes Care; 1998 May; 21(5):800-3. PubMed ID: 9589244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
